A large portion of patients taking prescription drugs that could affect driving may not be aware they could potentially be driving impaired, according to research…
The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received…
Less than two weeks after raising $22.5 million, San Diego cancer drug developer Impact Biomedicines has closed a deal for up to $90 million more. The…